Open AccessEarly administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion
Author(s) -
Д. И. Абдулганиева,
А. Л. Бакулев,
Elena Belousova,
А. В. Веселов,
Т. В. Коротаева,
А. М. Лила,
E. Yu. Loginova,
E. V. Sokolovskiy,
М. М. Хобейш,
М. В. Шапина,
О. Б. Щукина
Publication year - 2020
Publication title -
alʹmanah kliničeskoj mediciny
Language(s) - English
Resource type - Journals
eISSN - 2587-9294
pISSN - 2072-0505
DOI - 10.18786/2072-0505-2020-48-050
Subject(s) - psoriatic arthritis , medicine , expert opinion , psoriasis , genetically engineered , biological drugs , inflammatory bowel diseases , immune system , intensive care medicine , immunology , ulcerative colitis , disease , rheumatoid arthritis , biology , biochemistry , gene
Psoriasis (Ps), psoriatic arthritis (PsA), and inflammatory bowel diseases (IBDs) are characterized by a progressive course and commonly result in disability. Therefore, their early diagnosis with the assessment of a clinical phenotype and unfavorable prognostic factors and the timely initiation of therapy are important. The paper provides the expert consensus on the definition of the early stage of Ps, PsA, and IBDs, their treatment goals and main unfavorable prognostic factors. It also gives the rationale for the early use of biological agents in patients with immune-mediated inflammatory diseases.